z-logo
open-access-imgOpen Access
<p>Dual Targeting of the Epidermal Growth Factor Receptor Using Combination of Nimotuzumab and Erlotinib in Advanced Non-Small-Cell Lung Cancer with Leptomeningeal Metastases: A Report of Three Cases</p>
Author(s) -
Hongyu Xu,
Lin Zhou,
You Lü,
Xiaomei Su,
Cheng Peng,
Dong Liu,
Hui Gao,
Hua Li,
Weiwei Yuan,
Ling Zhang,
Tao Zhang
Publication year - 2020
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s230399
Subject(s) - medicine , nimotuzumab , erlotinib , epidermal growth factor receptor , lung cancer , oncology , epidermal growth factor , erlotinib hydrochloride , cancer research , receptor
Leptomeningeal metastases (LM) occur in 3-5% of patients with advanced non-small-cell lung cancer (NSCLC) and are associated with a dismal prognosis. We report three cases of NSCLC with LM who were treated with the combination of nimotuzumab and erlotinib. Magnetic Resonance Imaging (MRI) evaluation during follow-up showed significant improvement in cancer symptoms and decreased tumor size in all three patients. Grade 3 and 4 toxicities were rarely seen. Based on apparent efficacy of the regimen and fewer side effects, we suggest that nimotuzumab in combination with erlotinib may be a promising option for the treatment of NSCLC with LM.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here